ExeVir Bio Appoints a Chief Scientific Officer
Ghent, Belgium, 1 September 2023: ExeVir Bio, a biotech company developing robust single-domain antibody therapies for broad protection against infectious diseases, today announced Dr. Viki Bockstal as its Chief Scientific Officer (CSO) and Caroline Sagaert as its Head of Operations. Jean-Philippe Bultot will become the Company’s Head of Finance and lead ExeVir’s finance and accounting. […]
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
Dengue is a mosquito borne viral infection listed by WHO as top 10 threat for global health
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO)
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike
Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
xeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing agreement of up to EUR 25M (around USD 26.5m) with the European Investment Bank (EIB)*. The EIB financing will help advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19.
ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors
ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors.
Dr. Bolger has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development and Venture Investments at Johnson & Johnson Innovation – JJDC and at GlaxoSmithKline.
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.
ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.
ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.
ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody XVR011 which demonstrate in vitro neutralization activity against SARS-CoV-2 Variants of Concern Gamma and Delta. The company has also obtained grant funding of €3 million from the Flanders Agency for Innovation & Entrepreneurship (VLAIO) to accelerate clinical development of lead asset, the unique llama-derived VHH72-Fc antibody XVR011.
ExeVir Announces Close of $50 million/ EUR42 million Series A Financing
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.